Eyegate Pharmaceuticals, Inc. Warrants
EYEGW
EYEGW was delisted on the 5th of August, 2020.
5 hedge funds and large institutions have $377K invested in Eyegate Pharmaceuticals, Inc. Warrants in 2015 Q3 according to their latest regulatory filings, with 5 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$247K |
| 2 |
AIC
AWM Investment Company
New York
|
+$169K |
| 3 |
ICM
Ionic Capital Management
New York
|
+$34.4K |
| 4 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
+$7.3K |
| 5 |
VIA
Vantage Investment Advisors
State College,
Pennsylvania
|
+$3.09K |
Top Sellers
EYEGW Hedge Fund Activity: Q3 2015 in Review
5 of the 3,583 institutional investors tracked by Wall St. Rank reported a position in Eyegate Pharmaceuticals, Inc. Warrants (EYEGW) for Q3 2015, worth a combined $377K.
Buyers outnumbered sellers: 5 funds opened new EYEGW positions and 0 closed out — a net gain of 5 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Sabby Management, opening a new position worth an estimated $247K.
- 5 institutional investors held Eyegate Pharmaceuticals, Inc. Warrants (EYEGW) as of Q3 2015, up from 0 in Q2 2015.
- Funds reported $377K of Eyegate Pharmaceuticals, Inc. Warrants stock for Q3 2015.
- 5 funds opened new Eyegate Pharmaceuticals, Inc. Warrants positions in Q3 2015 and 0 closed out, a net change of +5 holders.
- The largest Eyegate Pharmaceuticals, Inc. Warrants buyer in Q3 2015 was Sabby Management, an estimated $247K added.
Based on aggregated 13F filings for Q3 2015.